TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial (Q34234217)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

Véronique Becette

18

object named as

Véronique Becette

0 references

9

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

20

object named as

Jonas Bergh

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

10

object named as

Emmanuel Blot

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

21

object named as

Richard Iggo

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Hervé Bonnefoi

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Martine Piccart

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jan Bogaerts

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Louis Mauriac

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Pierre Fumoleau

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Etienne Brain

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Thierry Petit

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Philippe Rouanet

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Khalil Zaman

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Tanja Cufer

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Alain Lortholary

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Elisabet Lidbrink

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sylvie André

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Saskia Litière

16

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Lissandra Dal Lago

17

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

David A Cameron

19

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

EORTC 10994/BIG 1-00 Study Investigators

22

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

11 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

527-539

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Mutant p53 gain-of-function in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Awakening guardian angels: drugging the p53 pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Blinded by the Light: The Growing Complexity of p53

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

p53 isoforms can regulate p53 transcriptional activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

The human tumour suppressor gene p53 is alternatively spliced in normal cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

A rapid PCR fidelity assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 July 2018

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

A simple p53 functional assay for screening cell lines, blood, and tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4172919

28 October 2018

Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of methods to detect p53 mutations in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21570352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(11)70094-8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34234217&oldid=2119127378"